Kazia Therapeutics Limited has entered into an At the Market Offering Agreement with Rodman & Renshaw LLC, allowing the company to offer and sell American Depositary Shares (ADSs) through Rodman as a sales agent. Each ADS represents 500 ordinary shares of the company. The offering will be made under Kazia's shelf registration statement on Form F-3, which was declared effective by the Securities and Exchange Commission on September 12, 2024. The company intends to use the net proceeds from this offering for general corporate purposes, including working capital, capital expenditures, research, clinical development, and potential acquisitions. Baker & McKenzie has provided a legal opinion on the validity of the ADSs and underlying ordinary shares. Kazia has also released supplemental risk factors to update its business disclosures.